IONIS PHARMACEUTICALS INC

For the period ended Jun 30, 2024. Filed Aug 1, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 1, 2024

IONS$28.19-9.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Stockholders’ Equity

Common Stock · Additional · Accumulated Other · Accumulated · Total Stockholders’
Description	Shares	Amount	Paid in Capital	Comprehensive Loss	Deficit	Equity
Balance at March 31, 2023	143,023	$143	$2,089,358	$(48,983)	$(1,553,948)	$486,570
Net loss	—	—	—	—	(85,290)	(85,290)
Change in unrealized losses, net of tax	—	—	—	(2,000)	—	(2,000)
Foreign currency translation	—	—	—	70	—	70
Issuance of common stock in connection with employee stock plans	144	—	2,390	—	—	2,390
Stock-based compensation expense	—	—	26,561	—	—	26,561
Balance at June 30, 2023	143,167	$143	$2,118,309	$(50,913)	$(1,639,238)	$428,301
Balance at March 31, 2024	145,845	$146	$2,270,047	$(34,964)	$(1,938,714)	$296,515
Net loss	—	—	—	—	(66,265)	(66,265)
Change in unrealized gains, net of tax	—	—	—	150	—	150
Foreign currency translation	—	—	—	(24)	—	(24)
Issuance of common stock in connection with employee stock plans	180	—	2,594	—	—	2,594
Stock-based compensation expense	—	—	30,728	—	—	30,728
Balance at June 30, 2024	146,025	$146	$2,303,369	$(34,838)	$(2,004,979)	$263,698

Index

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

Common Stock · Additional · Accumulated Other · Accumulated · Total Stockholders’
Description	Shares	Amount	Paid in Capital	Comprehensive Loss	Deficit	Equity
Balance at December 31, 2022	142,058	$142	$2,059,850	$(57,480)	$(1,429,625)	$572,887
Net loss	—	—	—	—	(209,613)	(209,613)
Change in unrealized gains, net of tax	—	—	—	6,393	—	6,393
Foreign currency translation	—	—	—	174	—	174
Issuance of common stock in connection with employee stock plans	1,109	1	4,949	—	—	4,950
Stock-based compensation expense	—	—	53,510	—	—	53,510
Balance at June 30, 2023	143,167	$143	$2,118,309	$(50,913)	$(1,639,238)	$428,301
Balance at December 31, 2023	144,341	$144	$2,215,098	$(32,645)	$(1,795,911)	$386,686
Net loss	—	—	—	—	(209,068)	(209,068)
Change in unrealized losses, net of tax	—	—	—	(2,056)	—	(2,056)
Foreign currency translation	—	—	—	(137)	—	(137)
Issuance of common stock in connection with employee stock plans	1,684	2	26,203	—	—	26,205
Stock-based compensation expense	—	—	62,068	—	—	62,068
Balance at June 30, 2024	146,025	$146	$2,303,369	$(34,838)	$(2,004,979)	$263,698

Index

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.